ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference

Rhea-AI Summary

ADMA Biologics, Inc. (Nasdaq: ADMA), a commercial biopharmaceutical company focused on specialty biologics, has announced its participation in the 2024 Cantor Global Healthcare Conference. The event will take place in New York, NY on September 17, 2024.

Key details:

• Adam Grossman, President and CEO, will participate in a fireside chat
• The presentation is scheduled for 3:05 p.m. ET
• A live audio webcast will be available on the company's investor relations website
• An archived version of the webcast will be accessible approximately two hours after the event

This conference provides ADMA Biologics with an opportunity to showcase its progress and strategy to investors and industry professionals in the healthcare sector.

News Market Reaction – ADMA

-5.93%

-5.93% Session move

In the trading session that priced this news, ADMA declined 5.93%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference in New York, NY on September 17, 2024, at 3:05 p.m. ET.

A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty biologics and human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com

FAQ

When is ADMA Biologics participating in the 2024 Cantor Global Healthcare Conference?

ADMA Biologics is participating in the 2024 Cantor Global Healthcare Conference on September 17, 2024, with a fireside chat scheduled for 3:05 p.m. ET.

Who will represent ADMA Biologics at the 2024 Cantor Global Healthcare Conference?

Adam Grossman, the President and Chief Executive Officer of ADMA Biologics, will represent the company at the conference.

Where can investors access the webcast of ADMA Biologics' presentation at the Cantor conference?

Investors can access the live audio webcast of ADMA Biologics' presentation under the 'Events & Webcasts' section in the investor relations area of the company's website at https://ir.admabiologics.com/events-webcasts.

How long after the event will the archived webcast of ADMA's presentation be available?

The archived webcast of ADMA Biologics' presentation will be available on the company's website approximately two hours after the event.